Epizyme, Inc. is a fully integrated, commercial-stage biopharmaceutical company committed to its mission of rewriting treatment for cancer and other serious diseases through novel epigenetic medicines. In addition to an active research and discovery pipeline, Epizyme has one U.S. FDA approved product, TAZVERIK® (tazemetostat), for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma (ES) who are not eligible for complete resection; adult patients with relapsed or refractory follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least two prior systemic therapies; and adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options. These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials. The Company is also exploring the treatment potential of tazemetostat in investigational clinical trials in other solid tumors and hematological malignancies, as a monotherapy and combination therapy in both relapsed and front-line disease settings. By focusing on the genetic drivers of disease, Epizyme seeks to match medicines with the patients who need them..
Company profile
Ticker
EPZM
Exchange
Website
CEO
Robert Bazemore
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
261349956
EPZM stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
23 Aug 22
EFFECT
Notice of effectiveness
17 Aug 22
EFFECT
Notice of effectiveness
17 Aug 22
EFFECT
Notice of effectiveness
17 Aug 22
POS AM
Prospectus update (post-effective amendment)
15 Aug 22
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Aug 22
S-8 POS
Registration of securities for employees (post-effective amendment)
13 Aug 22
S-8 POS
Registration of securities for employees (post-effective amendment)
12 Aug 22
S-8 POS
Registration of securities for employees (post-effective amendment)
12 Aug 22
S-8 POS
Registration of securities for employees (post-effective amendment)
12 Aug 22
Transcripts
EPZM
Earnings call transcript
2022 Q1
10 May 22
EPZM
Earnings call transcript
2021 Q4
1 Mar 22
EPZM
Earnings call transcript
2021 Q3
9 Nov 21
EPZM
Earnings call transcript
2021 Q2
9 Aug 21
EPZM
Earnings call transcript
2021 Q1
8 May 21
EPZM
Earnings call transcript
2020 Q4
23 Feb 21
EPZM
Earnings call transcript
2020 Q3
6 Nov 20
EPZM
Earnings call transcript
2020 Q2
4 Aug 20
EPZM
Earnings call transcript
2020 Q1
4 May 20
EPZM
Earnings call transcript
2019 Q4
24 Feb 20
Latest ownership filings
SC 13G/A
Palo Alto Investors LP
14 Feb 23
SC 13G/A
PRIMECAP MANAGEMENT CO/CA/
8 Sep 22
4
Michael F Giordano
16 Aug 22
4
CARL GOLDFISCHER
16 Aug 22
4
Kevin T Conroy
16 Aug 22
4
Victoria Richon
16 Aug 22
4
DAVID M MOTT
16 Aug 22
4
ROY A BEVERIDGE,
16 Aug 22
4
Shefali Agarwal
16 Aug 22
4
Jerald Korn
16 Aug 22
Financial summary
Quarter (USD) | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 72.58 mm | 72.58 mm | 72.58 mm | 72.58 mm | 72.58 mm | 72.58 mm |
Cash burn (monthly) | 2.12 mm | 758.17 k | 11.91 mm | 17.22 mm | 18.27 mm | 17.38 mm |
Cash used (since last report) | 44.37 mm | 15.88 mm | 249.53 mm | 360.65 mm | 382.62 mm | 364.08 mm |
Cash remaining | 28.21 mm | 56.70 mm | -176.96 mm | -288.08 mm | -310.05 mm | -291.50 mm |
Runway (months of cash) | 13.3 | 74.8 | -14.9 | -16.7 | -17.0 | -16.8 |
Institutional ownership, Q1 2023
23.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 3 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 57.89 mm |
Total shares | 40.07 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
RPI Finance Trust | 34.42 mm | $50.94 mm |
HCM HUTCHMED | 5.65 mm | $6.95 mm |
IPSEF Ipsen | 1.00 k | $0.00 |